{"id":"W4402565679","doi":"10.1016/j.annonc.2024.08.2307","title":"LBA1 A randomized multicenter open label phase III trial comparing enzalutamide vs a combination of Radium-223 (Ra223) and enzalutamide in asymptomatic or mildly symptomatic patients with bone metastatic castration-resistant prostate cancer (mCRPC): First results of EORTC-GUCG 1333/PEACE-3","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Enzalutamide; Medicine; Radium-223; Asymptomatic; Open label; Prostate cancer; Internal medicine; Oncology; Phases of clinical research; Urology; Randomized controlled trial; Clinical trial; Bone metastasis; Cancer; Androgen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002030418,0.0003134285,0.002180598,0.0005503964,0.00006531131,0.00004299485,0.0001811589,0.0001048189,0.00003787307],"category_scores_gemma":[0.0006082552,0.0002052197,0.0001116103,0.000586657,0.0005046794,0.0003203311,0.0001209005,0.0002306721,0.000001441922],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002165819,"about_ca_system_score_gemma":0.001031495,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002113691,"about_ca_topic_score_gemma":0.00217048,"domain_scores_codex":[0.9961259,0.0005604408,0.001854792,0.0004602909,0.0005650664,0.0004335224],"domain_scores_gemma":[0.9963834,0.001820045,0.0008312952,0.0002917751,0.0005075539,0.0001659534],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9688473,0.00755442,0.001956605,0.003118162,0.001571124,0.0001869385,0.006593485,0.00004423233,0.001576047,0.00009177767,0.0003939389,0.008065932],"study_design_scores_gemma":[0.9585831,0.01528179,0.002967923,0.004172453,0.0008588,0.00001121229,0.0004341191,0.01191832,0.005252065,0.0001175322,0.0001920639,0.0002105847],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9874133,0.002385507,0.00001572381,0.001604956,0.0001368128,0.007901132,0.0002724753,0.00002215561,0.0002478739],"genre_scores_gemma":[0.9965269,0.001255542,0.0007404825,0.00008311174,0.00002003888,0.0007894849,0.0002224059,0.00003686884,0.0003251933],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01187409,"threshold_uncertainty_score":0.8368617,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09570365100150162,"score_gpt":0.4280696711511847,"score_spread":0.332366020149683,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}